Medical devices, healthcare technology and the business of care
PMA approval · P060005

IMMULITE / IMMULITE 1000 AND IMMULITE 2000 FREE PSA ASSAYS

Siemens Medical Solutions Diagnostics Limited · Decision date May 11, 2007

MEDTECHLEDGER EXPLANATIONP060005

What did the FDA approve?

FDA approved the IMMULITE / IMMULITE 1000 and IMMULITE 2000 Free PSA assays on May 11, 2007. The devices quantitatively measure free prostate-specific antigen not bound to alpha 1-antichymotrypsin or other binding proteins in human serum, including serum collected in glass, plastic, and gel separator tubes.

The measured free PSA is used with the corresponding total PSA assay to calculate percent free PSA. That ratio is indicated as an aid in discriminating prostate cancer from benign disease in men 50 years or older with total PSA values between 4 and 10 ng/mL and digital rectal exam findings not suspicious of cancer. Prostate biopsy is required for diagnosis.

FDA approval order statement

APPROVAL FOR THE IMMULITE / IMMULITE 1000 AND IMMULITE 2000 FREE PSA ASSAY. THESE DEVICES ARE INDICATED FOR: THE IMMULITE / IMMULITE 1000 FREE PSA ASSAY IS INDICATED FOR IN VITRO DIAGNOSTIC USE WITH THE IMMULITE / IMMULITE 1000 ANALYZER FOR THE QUANTITATIVE MEASUREMENT OF FREE PROSTATE-SPECIFIC ANTIGEN (PSA) NOT BOUND TO ALPHA 1-ANTICHYMOTRYPSIN OR OTHER BINDING PROTEINS (UNCOMPLEXED) IN HUMAN SERUM (INCLUDING SERUM COLLECTED IN SERUM GLASS, SERUM PLASTIC AN SERUM GEL SEPARATOR TUBES). MEASUREMENT OF FREE PSA IS USED IN CONJUNCTION WITH IMMULITE / IMMULITE 1000 TOTAL PSA TO DETERMINE A RATIO OF FREE PSA TO TOTAL PSA (PERCENT FREE PSA). THE PERCENT FREE PSA IS USED AS AN AID IN DISCRIMINATING PROSTATE CANCER FROM BENIGN DISEASE IN MEN 50 YEARS OR OLDER WITH IMMULITE / IMMULITE 1000 TOTAL PSA VALUES BETWEEN 4 AND 10 NG/ML AND DIGITAL RECTAL EXAM (DRE) FINDINGS NOT SUSPICIOUS OF CANCER. PROSTATE BIOPSY IS REQUIRED FOR THE DIAGNOSIS OF PROSTATE CANCER. THE IMMULITE 2000 FREE PSA ASSAY IS INDICATED FOR IN VITRO DIAGNOSTIC USE WITH THE IMMULITE 2000 ANALYZER FOR THE QUANTITATIVE MEASUREMENT OF FREE PROSTATE-SPECIFIC ANTIGEN (PSA) NOT BOUND TO ALPHA 1-ANTICHYMOTRYPSIN OR OTHER BINDING PROTEINS (UNCOMPLEXED) IN HUMAN SERUM (INCLUDING SERUM COLLECTED IN SERUM GLASS, SERUM PLASTIC AN SERUM GEL SEPARATOR TUBES). MEASUREMENT OF FREE PSA IS USED IN CONJUNCTION WITH IMMULITE 2000 TOTAL PSA TO DETERMINE A RATIO OF FREE PSA TO TOTAL PSA (PERCENT FREE PSA). THE PERCENT FREE PSA IS USED AS AN AID IN DISCRIMINATING PROSTATE CANCER FROM BENIGN DISEASE IN MEN 50 YEARS OR OLDER WITH IMMULITE 2000 TOTAL PSA VALUES BETWEEN 4 AND 10 NG/ML AND DIGITAL RECTAL EXAM (DRE) FINDINGS NOT SUSPICIOUS OF CANCER. PROSTATE BIOPSY IS REQUIRED FOR THE DIAGNOSIS OF PROSTATE CANCER.
Regulatory pathway
Original PMA
Clinical specialty
Immunology
Decision date
May 11, 2007

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P060005
Regulatory pathway
Premarket approval application
Product code
MTG
Decision code
APPR
Decision date
May 11, 2007
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions.

Product code
MTG
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P060005 received

    Application receipt date recorded by FDA.

  2. P060005 · FDA decision

    APPR

  3. P060005/S027 · Related supplement

    IMMULITE Systems Free PSA

Timeline entries are records held by MedtechLedger for P060005. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P060005

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Medical Solutions Diagnostics LimitedPMA supplementSep 22, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Siemens Medical Solutions Diagnostics Limited

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Glyn Rhonwy Llanberis, Caernarfon, Gwynedd Ll55, 4EL

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records